Tag: GlobeNewswire

New collaboration combines Zscaler Autonomous Application Shield with Lightwell from IBM and Red Hat to help organizations reduce exposure between vulnerability disclosure and patch deployment through inline protection and validated remediation

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the cybersecurity platform for the AI era, today announced a collaboration with IBM and Red Hat to help organizations protect private applications during the period between vulnerability disclosure and patch deployment. The collaboration combines Zscaler Autonomous Application Shield, delivered through the Zscaler Zero Trust Exchange^TM security platform, with Lightwell from IBM and Red Hat to deliver adaptive, application-specific protection with validated software remediation in a single coordinated response.

The economics of exploitation have shifted. Capabilities that once required elite skills and weeks of manual effort are now widely available, and attackers are weaponizing newly disclosed vulnerabilities faster than enterprise patch cycles can respond. According to Mandiant’s M-Trends 2026 report, the mean time to exploit a vulnerability has fallen below zero, meaning vulnerabilities are increasingly exploited before a public patch exists. Patching remains necessary, but on its own it can no longer keep pace. Organizations need protection that can be applied at machine speed while remediation is prepared and deployed.

This collaboration extends Zscaler’s protection-first operating model for private applications, which assumes a remediation window will always exist and builds resilience around it: hide applications with Zscaler Private Access^TM (ZPA^TM) so they are harder to discover and target, segment access with Autonomous User-to-App Segmentation so a foothold does not become broad reachability, and shield reachable applications with Autonomous Application Shield so exploit attempts are stopped inline while the root cause is fixed. By uniting Zscaler Autonomous App Shield with Lightwell, the collaboration provides customers a coordinated path from immediate protection to durable fix.

Operating through the Zero Trust Exchange, Zscaler App Connectors continuously perform safe assessments of each private application’s exposure points and vulnerabilities. The Zscaler cloud individually evaluates each application, ensuring only necessary protections are applied. When a new vulnerability emerges, adaptive protections can be applied inline and in real time, without waiting for a patch. Through this collaboration, Lightwell helps Zscaler defend its customers from potential cyber threats, with Zscaler blocking exploit attempts immediately at the network level. Lightwell then provides validated remediations for affected open source software, enabling customers to fix the underlying flaw at the source.

“As attackers weaponize newly disclosed vulnerabilities faster than enterprises can respond, organizations need a way to protect private applications immediately while fixes are being prepared and deployed,” said Joby Menon, Senior Vice President of Product Management at Zscaler. “Our collaboration with IBM and Red Hat brings together inline, application-specific protection and validated remediation to help customers reduce risk during that gap.”

Through this collaboration, Zscaler, IBM, and Red Hat will deliver integrated capabilities across the application security lifecycle, addressing critical needs including:

• Exposure Discovery: Providing a current understanding of a private application’s actual risk profile, updated as fast as applications change, rather than relying on periodic scans.
• Preemptive, Application-Specific Protection: Bridging the gap between vulnerability and patching. Applying only the protections a given application needs during the gap between disclosure and patching, reducing exposure while remediation is underway and avoiding one-size-fits-all policy noise.
• Machine-Speed Response: Deploying protections inline and in real time when a new vulnerability emerges, informed by global threat intelligence from across Zscaler’s worldwide customer base.
• Validated Source-Level Remediation: Delivering tested software fixes through Lightwell so organizations can resolve the underlying vulnerability, with advisory and deployment support to prioritize and validate protections across complex environments.

“AI is shrinking the window between vulnerability discovery and vulnerability exploitation. A window that was months or weeks is now hours and minutes,” said Gunnar Hellekson, vice president and general manager, Lightwell, Red Hat. “Lightwell helps keep open source safe by patching and fixing these vulnerabilities at machine speed. Collaborating with partners like Zscaler brings Lightwell’s capabilities to the forefront of enterprise networks, mitigating potential vulnerabilities head-on while patches are applied to critical systems.”

Autonomous Application Shield is currently available through an Early Access Program. Availability, capabilities, and timing of the collaboration described herein are subject to change.

For a deeper dive into how Zscaler is helping protect against AI threats, please visit this blog.

Forward-Looking Statements

This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. These forward-looking statements include the expected performance and benefits of Zscaler Autonomous Application Shield and its collaboration with IBM and Red Hat, including the delivery of adaptive, machine-speed protection for private applications. These forward-looking statements are subject to the safe harbor provisions created by the Private Securities Litigation Reform Act of 1995. A significant number of factors could cause actual results to differ materially from statements made in this press release, including those factors related to Zscaler’s ability to achieve partner and customer adoption of Autonomous Application Shield and the collaboration described herein. Additional risks and uncertainties are set forth in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on September 3, 2026, which is available on our website at ir.zscaler.com and on the SEC’s website at www.sec.gov. Any forward-looking statements in this release are based on the limited information currently available to Zscaler as of the date hereof, which is subject to change, and Zscaler will not necessarily update the information, even if new information becomes available in the future.

About Zscaler

Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust Exchange^TM platform protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across 200+ public data centers globally and thousands of private sites at the edge, the SASE-based Zero Trust Exchange is the world’s largest in-line cloud security platform.

Media Contacts

Nick Gonzalez, Director of Public Relations, press@zscaler.com

Mastercard to lead customer sales engagement under worldwide agreement, expanding Rezolve Ai’s distribution and subscription revenue opportunity

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a global leader in AI-powered commerce and engagement, today announced a worldwide reseller agreement with Mastercard, establishing a new distribution channel for Rezolve Ai’s technology as businesses prepare for the next generation of AI-driven commerce.

Under the agreement, Mastercard is authorized to market, offer and sell subscriptions to Rezolve Ai’s software and SaaS services worldwide on a non-exclusive basis. The arrangement provides a commercial framework for bringing Rezolve Ai’s capabilities to Mastercard customers with Mastercard leading coordination of the sales process and contracting directly with resale customers.

The agreement covers capabilities spanning conversational commerce, intelligent search and product discovery, catalogue enrichment, personalization, recommendations and cart and checkout orchestration. Together, these technologies help businesses connect customer intent with relevant products and support shopping journeys from discovery through checkout handoff.

Daniel M. Wagner, Founder, Chairman and CEO of Rezolve Ai, said:
“This agreement gives Rezolve Ai a powerful new engine for international growth. Mastercard can market and sell our technology worldwide, with a defined commercial framework for turning customer opportunities into deployments and subscription revenues.

“As AI agents change how people shop, merchants need technology that understands their products, represents them accurately and helps turn demand into purchases. Rezolve Ai provides that intelligence.

“We are building Rezolve Ai to become essential infrastructure for agentic commerce. This agreement is a major step in taking our technology to market at scale.”

A worldwide distribution framework
The reseller agreement provides for coordinated sales activity, including joint customer evaluations, presentations, proposals and product demonstrations, supported by Rezolve Ai’s technical expertise.

For Rezolve Ai, the arrangement creates an opportunity to extend its commercial reach through Mastercard-led customer relationships. Individual deployments, including the selected capabilities, geography and commercial terms, will be agreed through separate statements of work.

Technology for the next generation of commerce
As shopping becomes increasingly conversational and agent-driven, businesses need systems that can interpret customer requests, organize and enrich product information, personalize recommendations and coordinate the steps towards purchase.

Rezolve Ai’s technology addresses these requirements across the merchant experience. The agreement also encompasses policy controls, governance and analytics capabilities designed to support deployment within customer-defined operating requirements.

“The opportunity is to make AI-powered commerce work for businesses at scale,” Wagner added. “We believe combining our commerce intelligence with this new worldwide distribution channel can help accelerate adoption and establish Rezolve Ai at the center of that transformation.”

About Rezolve Ai

Rezolve Ai is a global leader in AI-powered commerce and engagement. Its technology helps retailers, brands, financial institutions and commerce platforms create intelligent, personalized customer experiences across search, discovery, engagement and transaction journeys.

Rezolve Ai’s platform is designed to connect consumers, merchants, banks and payment providers through intelligent commerce infrastructure that makes customer interactions more relevant, measurable and valuable. Through its AI-powered commerce capabilities and Reward’s financial engagement platform, Rezolve Ai is building the infrastructure for the next generation of personalized and agentic commerce.

Media Contact
Urmee Khan
Global Head of Communications
urmeekhan@rezolve.com
+44 7576 094 040

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the expected benefits of Rezolve Ai’s worldwide reseller agreement with Mastercard, potential customer opportunities, international expansion, adoption of the Company’s technology, growth in software and SaaS subscription revenues, and the development of agentic commerce.

These statements reflect management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These include the parties’ ability to convert sales opportunities into signed statements of work and deployments; the timing and extent of customer adoption; demand for the Company’s solutions; competition; technological and regulatory developments; and other risks described in the Company’s filings with the Securities and Exchange Commission. The reseller agreement does not guarantee customer orders, minimum purchase volumes or revenues.

Forward-looking statements speak only as of the date of this release. Rezolve Ai undertakes no obligation to update them, except as required by law.

Martela Corporation, inside information, October 5, 2026 at 15.00 (EEST)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, NEW ZEALAND, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Martela Corporation (“Martela” or the “Company“) announced on 29 September 2026 that the Company’s Extraordinary General Meeting had approved the Board of Directors’ proposals to authorise the Board of Directors to resolve on a directed share issue against consideration and the combination of share series. The Company announced on 30 September 2026 that Martela’s Board of Directors has resolved on a directed share issue against consideration of approximately EUR 6–8 million, under which it will offer for subscription, in deviation from the shareholders’ pre-emptive subscription right, initially a maximum of 17,777,777 new shares of the Company corresponding to the existing series A shares, representing the Company’s sole series of shares following the combination of share series (the “Offer Shares“) (the “Share Issue“). The subscription period for the Share Issue ended today on 5 October 2026 at 10:00 (EEST) and according to the preliminary result, Martela will receive gross proceeds of approximately EUR 7.2 million from the Share Issue.

According to the preliminary result, a total of 15,907,707 Offer Shares were subscribed for in the Share Issue, corresponding to approximately 89 per cent of the Offer Shares. The subscription price in the Share Issue was EUR 0.45 per Offer Share.

Panu Ala-Nikkola, CEO, Martela Corporation: “I would like to thank all our new and existing shareholders for their support and confidence in Martela’s future. With the proceeds from the share issue, the Company will strengthen its financial position and liquidity, while creating greater flexibility to continue the necessary development and efficiency measures. The key objective of the planned measures is to improve competitiveness, profitability and cash flow”.

The final results of the Share Issue will be published on or about 6 October 2026 after the Board of Directors of Martela has approved the subscriptions made in the Share Issue. Allocation of Offer Shares will be made in accordance with the terms and conditions of the Share Issue. As a result of the Share Issue, the combination of share series and the related directed share issue without consideration, the total number of shares in Martela will increase by a maximum of 16,058,907 from 4,639,212 to a maximum of 20,698,119 provided that the Board of Directors of Martela approves the subscriptions made in the Share Issue, the combination of the Company’s share series is registered with the Trade Register and the directed share issue without consideration is carried out at its maximum amount, i.e. 151,200 shares. The Offer Shares issued in the Share Issue amount to approximately 77 per cent of all shares in Martela following the Share Issue provided that the combination of share series is registered with the Trade Register.

The Offer Shares will be registered with the Finnish Trade Register maintained by the Finnish Patent and Registration Office on or about 12 October 2026. Trading in the Offer Shares on Nasdaq Helsinki Ltd is estimated to commence on 13 October 2026. The Offer Shares carry the right to dividends and other shareholder rights once the Offer Shares have been registered with the Trade Register. Following the registration of the combination of the share series with the Trade Register on or about 12 October 2026, the Offer Shares carry the same rights as the Company’s other shares.

Advisors

Aktia Alexander Corporate Finance Oy is acting as Martela’s financial advisor and as the Lead Manager of the Share Issue. Castrén & Snellman Attorneys Ltd is acting as Martela’s legal advisor.

MARTELA CORPORATION
BOARD OF DIRECTORS

FOR FURTHER INFORMATION, PLEASE CONTACT:

CEO, Panu Ala-Nikkola
tel +358 50 502 4728

CFO, Henri Berg
tel +358 40 836 5464

Chairman of the Board, Tapio Pajuharju
tel +358 50 5774 200
DISTRIBUTION:

NASDAQ Helsinki, key news media, www.martela.com

MARTELA CORPORATION:

Martela is a Nordic leader specialising in user-centric working and learning environments. With over 80 years of experience, we create the best places to work and offer our customers the Martela Lifecycle solutions which combine furniture and related services into a seamless whole.

IMPORTANT NOTICE:

The distribution of this release may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such relevant legal restrictions. The information contained herein is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, New Zealand, Japan, Singapore, South Africa or any other jurisdiction in which the release, publication or distribution would be unlawful. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This release is not directed to, and is not intended for release, publication or distribution to or use by, any person or entity that is a citizen or resident of, or is located in, any locality, state, country or other jurisdiction where such release, distribution, publication, availability or use would violate law or regulation or which would require any registration or licensing within such jurisdiction.

This release does not constitute a prospectus as defined in the Prospectus Regulation nor a document containing the information set out in Annex IX of the Prospectus Regulation and, as such, it does not constitute or form part of, and should not be construed as, an offer to sell, or a solicitation or invitation of any offer to buy, acquire or subscribe for, any securities or an inducement to enter into investment activity in relation to any securities.

No part of this release, nor the fact of its release, publication or distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the pertinence, accuracy, completeness or correctness of the information or the opinions contained herein. Neither the Company nor any of its respective affiliates, advisors or representatives or any other person shall have any liability whatsoever (in negligence or otherwise) for any loss, however arising, from any use of this release or its contents or otherwise arising in connection with this release. Each person must rely on their own examination and analysis of the Company, its subsidiaries, its securities and the transactions, including the merits and risks involved.

Aktia Alexander Corporate Finance Oy acts exclusively for the Company and no one else in connection with the arrangement. Aktia Alexander Corporate Finance Oy does not regard any other person as its client in relation to the arrangement. Aktia Alexander Corporate Finance Oy is not responsible to anyone other than the Company for providing the protections afforded to its clients, nor for giving advice in relation to the arrangement or any transaction or arrangement referred to herein.

This release includes forward-looking statements. These statements may not be based on historical facts, but are statements about future expectations. When used in this release, the words “aims,” “anticipates,” “assumes,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “should,” “will,” “would” and similar expressions as they relate to the Company and the transactions identify certain of these forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. These forward-looking statements are based on present plans, estimates, projections and expectations and are not guarantees of future performance. They are based on certain expectations, which, even though they seem to be reasonable at present, may turn out to be incorrect. Such forward-looking statements are based on assumptions and are subject to various risks and uncertainties. Readers should not rely on these forward-looking statements. Numerous factors may cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied in the forward-looking statements. Neither the Company nor any of its affiliates, advisors, representatives or any other person undertakes any obligation to review, confirm or to publicly release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise following the date of this release.

AssureChain, a dedicated subnet of MindChain, will run every insurance function on-chain, while MindChain provides settlement and anchoring to Ethereum

MATAWAN, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) — via IBN – MindWave Innovations Inc. USA (“MindWave”), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), has signed a 2-year master maintenance and service agreement with Delaware-based BlockAssure Inc. (“BlockAssure”) to build, deploy and operate AssureChain, a dedicated subnet of MindChain that will run BlockAssure’s insurance and reinsurance operations on-chain.

For MindWave, this is an important expansion of its U.S. business. It takes the company’s technology work into insurance and reinsurance, and it is a long-term build-and-operate contract with a U.S. client.

“BlockAssure chose us to build AssureChain, and it is exactly the kind of work we want to do for U.S. clients,” said Dr. Vin Menon, Chief Executive Officer of MindWave Innovations Inc. USA.

MindWave will design, develop, security-audit and deploy AssureChain, then host, operate and maintain it once it goes live. All of BlockAssure’s insurance work will happen on AssureChain: contracts, policies, premium and payment entries, reinsurance treaties and claims processing, from the start of a policy to the settlement of a claim. MindChain’s job is narrower – It provides the settlement layer and anchors AssureChain’s records to Ethereum.

MindWave will earn contracted development fees, payable in quarterly installments, with later operating and maintenance fees to be agreed. The agreement also provides for an allocation to MindWave equal to 20% of the total supply of AssureCoin, a digital token BlockAssure plans to create within the MindChain network, delivered when the token is created. The allocation is fully vested on delivery, and anti-dilution terms maintain MindWave’s 20% share if additional AssureCoin is issued during the term or for two years afterward.

The aim is straightforward: BlockAssure handles the market relationships, and MindWave builds and runs the network underneath them. Contracts, policies, payments, treaties and claims all run on AssureChain. Because it settles through MindChain and anchors to Ethereum, you can follow any claim from the policy that created it to the recovery that closes it outFor the length of the agreement, MindWave is BlockAssure’s exclusive blockchain provider for AssureChain.

The two companies have divided the work along clear lines. BlockAssure will lead underwriting and claims decisions, licensing, and its relationships with insurers, reinsurers and brokers. MindWave supplies the infrastructure and the technical services needed to run AssureChain. It acts only as the technology provider.

AssureChain is made up of four modules and a data oracle: insurance contracts; policy issuance and lifecycle management, including premium and payment entries; reinsurance treaties and facultative placements; and claims processing from notification through assessment, settlement and reinsurance recovery. The oracle feeds verified parametric, environmental, catastrophe, market and identity data onto AssureChain, which lets a parametric claim trigger automatically once a pre-agreed threshold is met.

Each claim on AssureChain can be traced back to the policy, contract and treaty it came from, and MindChain anchors those records to Ethereum. BlockAssure and its counterparties therefore work from one verifiable record, from placement to settlement. Each module will be independently security-audited before production, and personal data will not be written on-chain except in hashed or tokenized form.

The agreement took effect on Oct. 4, 2026. Development is planned over four quarters against agreed milestones, and BlockAssure will acceptance-test each module. Once the first module is accepted, MindWave takes on hosting, validator operations, maintenance, security patches and helpdesk support.

After the initial 2-year term, the agreement renews automatically for one-year periods unless either party gives 90 days’ notice.

About MindWave Innovations Inc. USA
MindWave Innovations Inc. USA, a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), develops technology infrastructure and digital solutions for blockchain-enabled applications, data-driven platforms, and emerging commercial ecosystems.

Through projects such as AssureChain, MindWave is expanding the application of its technology into insurance, reinsurance and digital-asset-enabled insurance models.

For more information, visit https://www.mindwaveinnovations.com/

About MindChain
MindChain is a blockchain infrastructure developed within the MindWave ecosystem to support transparent, traceable, and verifiable digital transactions. It is designed to provide the underlying ledger capabilities required for applications involving digital assets, registries, tokenized ecosystems, and decentralized services.

About AssureChain
AssureChain is BlockAssure’s dedicated insurance and reinsurance network and runs as a subnet of MindChain. Every insurance function runs on AssureChain. MindChain handles settlement and anchoring to Ethereum.

About BlockAssure Inc.
BlockAssure Inc. is a Delaware corporation developing an insurance and reinsurance platform supported by digital asset capital.

For more information, visit https://www.blockassure.io/

Forward-Looking Statements
This announcement contains forward-looking statements regarding the development, implementation, anticipated capabilities, and potential performance of AssureChain, and the potential creation and allocation of AssureCoin. These statements are based on current expectations and are subject to risks and uncertainties, including development timelines, achievement of project milestones, technical performance, regulatory requirements, BlockAssure’s licensing, whether and when AssureCoin is created, and market acceptance. Actual results may differ materially from those expressed or implied. The company undertakes no obligation to update these statements except as required by applicable law.

Media and Investor Relations
MindWave Innovations Inc. USA
Website : https://www.mindwaveinnovations.com
Email : contact@mindwaveinnovations.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

STMicroelectronics announces status
of common share repurchase program

Disclosure of Transactions in Own Shares – Period from September 28, 2026 to October 2, 2026

AMSTERDAM – October 05, 2026 — STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated June 21, 2024. The Program was approved by a shareholder resolution dated May 22, 2024 and by the supervisory board.

STMicroelectronics N.V. (registered with the trade register under number 33194537) (LEI: 213800Z8NOHIKRI42W10) announces the repurchase (by a broker acting for the Company) on the regulated market of Euronext Paris, in the period between September 28, 2026 to October 2, 2026 (the “Period”), of 310,000 ordinary shares (equal to 0.03% of its issued share capital) at the weighted average purchase price per share of EUR 47.1205 and for an overall price of EUR    14,607,365.00.

The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from share option programmes, or other allocations of shares, to employees or to members of the administrative, management or supervisory bodies of the issuer or of an associate company.

The shares may be held in treasury prior to being used for such purpose and, to the extent that they are not ultimately needed for such purpose, they may be used for any other lawful purpose under article 5(2) of the Market Abuse Regulation.

Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STMicroelectronics (ISIN: NL0000226223), in detailed form.

 Transactions in Period

Dates of transaction	Number of shares purchased	Weighted average purchase price per share (EUR)	Total amount paid (EUR)	Market on which the shares were bought (MIC code)
28-Sep-26	70,000	45.5195	3,186,365.00	XPAR
29-Sep-26	60,000	47.2025	2,832,150.00	XPAR
30-Sep-26	60,000	46.8866	2,813,196.00	XPAR
1-Oct-26	60,000	47.0945	2,825,670.00	XPAR
2-Oct-26	60,000	49.1664	2,949,984.00	XPAR
Total for Period	310,000	47.1205	14,607,365.00

Following the share buybacks detailed above, the Company holds in total 15,583,565 treasury shares, which represents approximately 1.7% of the Company’s issued share capital.

In accordance with Article 5(1)(b) of the Market Abuse Regulation and Article 2(3) of Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual trades in the Program are disclosed on the ST website (https://investors.st.com/stock-and-bond-information/share-buyback).

About STMicroelectronics
At ST, we are 49,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com   

For more information, please contact:

INVESTOR RELATIONS
Jérôme Ramel
EVP Corporate Development & Integrated External Communication
Tel: +41.22.929.59.20
jerome.ramel@st.com    
  
MEDIA RELATIONS
Alexis Breton
Group VP Corporate External Communications
Tel: +33.6.59.16.79.08
alexis.breton@st.com

Attachment

• C3414C — Oct 5 2026 — Disclosure of transactions in Own Shares PR_FINAL FOR PUBLICATION

ORION CORPORATION
PRESS RELEASE
05 OCTOBER 2026 at 8:00am ET

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing 
Milestone marks Orion Pharma’s entry into clinical-stage biologics (large molecules) and advances the company’s immuno-oncology portfolio

ESPOO, Finland, CAMBRIDGE, United Kingdom and CAMBRIDGE, M.A., October 5, 2026 – Orion Corporation (Orion Pharma) today announced that the first patient has been dosed in the BICIDES Phase 1/2 clinical trial evaluating the safety, pharmacokinetics and preliminary anti-tumor activity of ODM-216, an investigational bispecific antibody simultaneously targeting PVRIG and PD-L1 in patients with advanced solid tumors. ODM-216 is Orion Pharma’s first biologic candidate and first immuno-oncology treatment to enter clinical testing in humans. ODM-216 is a key component of Orion Pharma’s immuno-oncology portfolio, including several assets in the pre-clinical pipeline.

“Treating the first patient in the ODM-216 BICIDES study is a significant achievement for Orion Pharma and an important moment in the evolution of our long-term global R&D strategy to expand our capabilities beyond small molecules and into biologics,” said Professor Outi Vaarala, M.D., Ph.D., Executive Vice President, Research & Development at Orion Pharma. “As both our first biologic and first immuno-oncology candidate to reach clinical stage, ODM-216 reflects our team’s commitment to discovering and advancing innovative new treatment approaches that further strengthen our foundation for a diversified future oncology pipeline. We look forward to evaluating ODM-216 in the clinic as we continue our mission for people living with difficult-to-treat cancers.”

ODM-216’s advancement is fueled by Orion Pharma’s internal research & development efforts across its global R&D organization located in Finland, the UK and the US, including the company’s Biologics Research & Development Centre in Cambridge, UK, which was established in 2025 to strengthen Orion Pharma’s biologics capabilities.

The Phase 1/2 trial is known as BICIDES and more information can be found on ClinicalTrials.gov using identifier: NCT07805252.

About ODM-216
ODM-216 is an investigational anticancer medicine being developed by Orion Pharma. Designed to activate anti-tumor immune responses, ODM-216 is a bispecific antibody simultaneously targeting PVRIG and PD-L1, two immune-regulatory pathways involved in cancer growth and progression.

Media contact:
Maddie Davidshofer, Lead, Scientific & Pipeline Communications
tel. +1 857 529 0169

Investor contact:
Tuukka Hirvonen, Head of Investor Relations
tel. +358 10 426 2721                                                 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.

Oncotelic’s AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development.

Source: Oncotelic Therapeutics, Inc.

AGOURA HILLS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), together with its wholly owned subsidiary Pet2DAO, Inc. (“Pet2DAO”), today announced that PDAOAI, the Company’s AI-powered drug discovery platform, is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. The invitation accompanies two keynote presentations at Drug Discovery 2026, including a hepatocellular carcinoma case study illustrating how Partitioned Literature Aggregation can generate testable research hypotheses.

BIO REBOOT Opens Registration

Through BIO REBOOT, individuals and teams can bring research questions, technical expertise and drug discovery ideas to the PDAOAI community. Registration is free at https://pdaoai.com/bio-reboot.

Selected projects may be considered for startup funding and Oncotelic support spanning validation, formulation, regulatory planning and clinical development. Funding, platform access and development support are subject to scientific review, available resources and agreed terms.

“We’re excited about the discoveries we’re making with PDAOAI, and we’re opening the door for others to build with us,” said Saran Saund, Chief Business Officer of Oncotelic. “Our hepatocellular carcinoma case study is one example: PDAOAI helped identify a candidate four-gene signature, opening a new direction for research. Through BIO REBOOT, we want to help collaborators turn promising ideas into discoveries that can be tested and developed.”

“Researchers need a faster, more practical way to move from a broad question to a set of relevant papers they can inspect and discuss,” said Scott Myers, Product Manager at Oncotelic. “Our focus with PDAOAI is helping them find relevant material, understand the sources behind an answer and decide what question deserves further investigation.”

Drug Discovery 2026 Presentations

Saran Saund, Chief Business Officer, and Scott Myers, Product Manager, will deliver keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, taking place October 7–9, 2026, at the Hilton San Francisco Airport Bayfront in Burlingame, California. Saund will also participate in a panel discussion on October 8.

The conference brings together pharmaceutical and biotechnology professionals, academic researchers and drug development specialists to discuss advances in drug discovery and lead optimization. The organizer lists speakers from Amgen, Eli Lilly and Company, the National Institutes of Health, Harvard Medical School and Stanford University.

Saran Saund — Thursday, October 8, 2026, 10:00–10:30 a.m. Pacific Time

Partitioning 4.4 million Abstracts by Disease Turns a Literature Review into a Discovery: A Four-Gene mTOR Signature Defining a Candidate Hepatocellular Carcinoma Population

Scott Myers — Wednesday, October 7, 2026, 11:20–11:50 a.m. Pacific Time

The Infinity Problem: AI Search Aggregation for Biomedical Knowledge Discovery in Drug Development

Panel Discussion

On October 8, Saund will also join the panel discussion titled “The Future of Drug Discovery: Integrating AI, Innovative Technologies, and Multidisciplinary Research.” The session will address the role of AI and collaboration across disciplines in the next generation of drug discovery.

About PDAOAI and Pet2DAO

PDAOAI is an AI-powered drug discovery platform developed by Oncotelic Therapeutics, Inc. (OTCQB: OTLC). Oncotelic and its wholly owned subsidiary, Pet2DAO, Inc., support the BIO REBOOT collaboration initiative. Built on a current index of 29 million PubMed abstracts, PDAOAI maps biomedical literature into a high-dimensional vector space and applies mathematical algorithms to uncover relationships across genes, pathways and diseases. Its Partitioned Literature Aggregation (PLA) method analyzes disease-specific literature groups separately before combining the findings, helping limit the influence of differences in publication volume. By connecting evidence scattered across decades of research, PDAOAI surfaces candidate drug targets and testable hypotheses for drug discovery, repurposing and therapeutic development, with evidence traceable to source publications. For more information, visit www.pdaoai.com.

About Oncotelic

Oncotelic Therapeutics, Inc. develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications. The Company also develops the PDAOAI platform to support its work in drug discovery and development. Additional information is available at www.oncotelic.com.

Oncotelic’s Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may,” “expect,” “anticipate,” “plan,” “intend,” “believe,” “estimate” and “will” can identify forward-looking statements. Forward-looking statements in this release include statements regarding the Company’s anticipated conference participation, planned presentations and panel discussion, the development and use of PDAOAI and PLA, and their potential to support hypothesis generation and further scientific investigation. Forward-looking statements also include plans for BIO REBOOT collaborations and potential startup funding, platform access and drug development support. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive. The Company faces known and unknown risks, including the risk factors described in the Company’s 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026 and in the Company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the Company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.

Contact Information
For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com
BIO REBOOT collaboration inquiries: Scott Myers, scott.myers@oncotelic.com

Field crews demobilizing following completion of geological mapping, prospecting and soil and rock sampling

CALGARY, Alberta, Oct. 05, 2026 (GLOBE NEWSWIRE) — Northern Discovery Metals Inc. (CSE: NOR) (FSE: M1V0) (“Northern Discovery” or the “Company”) is pleased to announce that Stage 1 fieldwork at the Vent Copper Project (“Vent” or the “Project”) is complete and field crews are demobilizing. The Project is located in the Alberni Mining Division on Vancouver Island, British Columbia, where the Company holds an option to acquire up to a 100% interest.

The program was carried out by Geomap Exploration Inc. and included geological mapping, prospecting, and soil and rock sampling. Building on the progress reported in the Company’s September 22, 2026 news release, the work was designed to improve the geological understanding of priority areas and assess the relationships between geochemical responses, geological contacts, structures, alteration and veining.

“With the fieldwork complete, our focus turns to evaluating the results and determining where to concentrate further exploration,” said Jared Suchan, Ph.D., P.Geo., Chief Executive Officer of Northern Discovery Metals. “Bringing the new mapping and sampling together with our existing geophysical information will help us assess which areas warrant more detailed investigation and what work is needed to advance them.”

The Company plans to integrate the field observations and laboratory results, following review and validation, with its existing geological, geochemical and airborne magnetic and VLF-EM datasets. This work will support refinement of the geological model and the ranking of areas for follow-up. Depending on the results, subsequent exploration may include focused induced polarization surveys or other ground geophysical work. The scope and timing of further fieldwork will be determined after evaluation of the Stage 1 results. No analytical results from the program are reported in this release. The Company intends to provide a further update following receipt and review of the results.

Qualified Person Statement

Jared Suchan, Ph.D., P.Geo., Chief Executive Officer and Director of the Company, and a “Qualified Person” within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical contents of this news release.

For a further discussion of the Company’s QA/QC and data verification procedures and processes, please see the technical report entitled, Technical Report on the Vent Copper Property, Alberni Mining Division, British Columbia, Canada, NTS Map 092F03W,” dated July 22, 2026, a copy of which may be obtained under the Company’s profile at www.sedarplus.ca.The Property is an exploration-stage mineral property with no current mineral resource or mineral reserve estimates.

About Northern Discovery Metals Inc.

Northern Discovery Metals Inc. is a mineral exploration company focused on the acquisition, exploration and advancement of mineral properties in Canada. The Company is exploring for copper at its Vent Project on Vancouver Island, British Columbia. Northern Discovery Metals intends to advance the Project through systematic exploration and evaluation of its mineral potential.

On Behalf of the Board of Directors

Jared Suchan

Chief Executive Officer and Director

Phone: (604) 294-3020

Email: info@northerndiscoverymetals.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential”, “scheduled”, “targeted”, “may”, “will”, “could”, “would” and similar expressions, or statements that certain events or conditions “will”, “may” or “could” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the expected timing, duration, scope and focus of the exploration program at the Property; the evaluation and follow-up of geochemical responses, magnetic and VLF-EM responses and other evidence encountered during the program; the integration of program results with existing geological, geochemical and geophysical information; the refinement of the Company’s geological model and ranking of priority areas; the potential identification of coherent geological and geochemical targets; the possible undertaking of focused induced-polarization or other ground geophysical work; the potential refinement and ranking of drill targets; and the Company’s plans to systematically explore, evaluate and advance the Property. 

Forward-looking statements are based on management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release, including assumptions regarding the availability of personnel, contractors, equipment, supplies and financing on acceptable terms; the accuracy, reliability and completeness of historical and existing geological, geochemical and geophysical data; the ability to obtain and maintain all required permits, approvals and access arrangements; suitable weather, access and field conditions; and the absence of material adverse changes in applicable laws, commodity prices, market conditions or the Company’s business and financial position. Although the Company considers these assumptions reasonable based on information currently available, they may prove to be incorrect. 

Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date hereof, and the Company undertakes no obligation to update or revise them to reflect new events or circumstances, except as required by applicable securities laws. 

The CSE has neither approved nor disapproved the information contained herein.

MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) — Cannara Biotech Inc. (“Cannara”, the “Company”, “us” or “we”) (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities in Québec spanning over 1,600,000 sq. ft., is pleased to announce an expansion of its long-term international supply agreement (the “Agreement”) with Curaleaf International Limited (“Curaleaf”), previously announced on July 14, 2026. If fully realized, the amended Agreement has a potential aggregate contract value of approximately C$34 million over its two-year term, compared with up to C$21 million under the original Agreement, based on committed supply volumes and the terms and conditions of the Agreement. The expanded relationship builds on Cannara’s first long-term international supply commitment and provides an opportunity to grow international sales through Curaleaf’s established distribution network while continuing to support the Company’s Canadian growth strategy.

“The expansion of our agreement reflects the strong relationship we are building with Curaleaf and the quality of the cannabis we have supplied from our Valleyfield facility,” said Zohar Krivorot, Founder and Chief Executive Officer of Cannara. “We see a meaningful opportunity to grow together as partners, supplying Québec-grown cannabis to international medical markets while continuing to execute our growth strategy here in Canada.”

“This expanded agreement demonstrates our ability to grow within the cultivation infrastructure we already own at Valleyfield, where we now have 15 of our 24 grow rooms active,” said Niko Sosiak, Chief Operating Officer of Cannara. “With a fully funded build-out plan, our remaining capacity gives us a clear runway to scale production as demand grows, while maintaining consistent quality and the cost discipline that support our growth in Canada and internationally.”

Curaleaf also continues to support Cannara’s pursuit of EU-GMP certification for its processing center at Valleyfield. In the interim, cannabis flower supplied under the Agreement will be dried and processed under EU-GMP conditions at Curaleaf’s EU-GMP certified facility in Canada before release into international medical markets.

CONTACT

Scott Carroll, PhD, MBA
Vice President, Investor Relations & Commercial Strategy
scott.carroll@cannara.ca

ABOUT CANNARA

Cannara Biotech Inc. (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products. Cannara owns two mega facilities based in Québec spanning over 1,600,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Leveraging Québec’s favourable energy costs, Cannara maintains an efficient, low-cost production model. For more information, please visit cannara.ca.

ABOUT CURALEAF

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. Curaleaf International’s unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. For more information, please visit ir.curaleaf.com

CAUTIONARY STATEMENT REGARDING “FORWARD-LOOKING” INFORMATION

This news release may contain “forward-looking information” within the meaning of Canadian securities legislation (“forward-looking statements”). These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. Forward-looking statements relate to future events or future performance and reflect Company management’s expectations or beliefs regarding future events and include, but are not limited to, statements regarding the anticipated benefits of the amended Agreement, the timing and extent of the increased cultivation allocation, expected plant volumes and supply of cannabis flower, the potential aggregate contract value and the extent to which it is realized, anticipated international sales and Canadian growth, the parties’ performance of their respective obligations, the pursuit and potential receipt of EU-GMP certification and future dried-flower pricing.

In certain cases, forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur” or “be achieved” or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including “may,” “future,” “expected,” “intends” and “estimates.” By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in, or implied by, such forward-looking information. These risks and uncertainties include, but are not limited to, the risk factors which are discussed in greater detail under “Risk Factors” in the Company’s AIF available on SEDAR+ at www.sedarplus.ca and under the “Investor Area” section of our website at https://www.cannara.ca/en/investor-area.

Other risks not presently known to the Company or that the Company believes are not significant could also cause actual results to differ materially from those expressed in its forward-looking statements. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, readers are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions were made in preparing the forward-looking information concerning the availability of capital resources, business performance, market conditions, as well as customer demand. Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein is provided as of the date hereof, and we do not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

ASML reports transactions under its current share buyback program

VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML’s current share buyback program.

Date	Total repurchased shares	Weighted average price	Total repurchased value
28-Sep-26	50,000	€1,529.45	€76,472,475
29-Sep-26	57,000	€1,596.29	€90,988,564
30-Sep-26	50,000	€1,609.32	€80,466,190
1-Oct-26	60,000	€1,602.84	€96,170,670
2-Oct-26	60,000	€1,639.73	€98,384,082

ASML’s current share buyback program was announced on 28 January 2026. Further details are available on our website.

This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).

About ASML

ASML is a leading supplier to the semiconductor industry. The company provides chipmakers with hardware, software and services to mass produce the patterns of integrated circuits (microchips). Together with its partners, ASML drives the advancement of more affordable, more powerful, more energy-efficient microchips. ASML enables groundbreaking technology to solve some of humanity’s toughest challenges, such as in healthcare, energy use and conservation, mobility and agriculture. ASML is a multinational company headquartered in Veldhoven, the Netherlands, with offices across EMEA, the US and Asia. Every day, ASML’s more than 44,100 employees (FTE) challenge the status quo and push technology to new limits. ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. Discover ASML – our products, technology and career opportunities – at www.asml.com.

Media Relations contacts Monique Mols, phone +31 6 528 444 18

Investor Relations contacts Jim Kavanagh, phone +31 40 268 3938 Pete Convertito, phone +1 203 919 1714 Peter Cheang, phone +886 3 659 6771